Martingale Asset Management L P Revance Therapeutics, Inc. Transaction History

Martingale Asset Management L P

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 11, 2022	SELL	$12.46 - $27.87 $360,268 - $805,833	-28,914 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$25.78 - $33.21 $554,270 - $714,015	21,500 Added 289.99%	28,914 $805,000
Q2 2021 Aug 13, 2021	BUY	$26.8 - $31.84 $198,695 - $236,061	7,414 New	7,414 $219,000
Q4 2020 Feb 10, 2021	SELL	$23.41 - $28.34 $1.75 Million - $2.12 Million	-74,713 Closed	0 $0
Q3 2020 Nov 12, 2020	SELL	$23.23 - $34.3 $1.17 Million - $1.73 Million	-50,498 Reduced 40.33%	74,713 $1.88 Million
Q2 2020 Aug 10, 2020	BUY	$12.6 - $26.55 $1.58 Million - $3.32 Million	125,211 New	125,211 $3.06 Million

234

82.8M

680K

896K

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

Get notified when there are updates to the investment portfolio of Martingale Asset Management L P, based on Form 13F filings with the SEC.

Stay updated on Martingale Asset Management L P with notifications on news.